Canaccord raised the firm’s price target on AxoGen (AXGN) to $27 from $24 and keeps a Buy rating on the shares. The fim said posted yet another strong Q as the company saw traction across its portfolio, growing over 23%, significantly above consensus expectations, and raising guidance to over 19% growth for the FY25.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN: